newsfilter
← Latest News
PR Newswire·

Promising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient included

Continued tumor control in the liver in 7 of the first 10 patients after three months of treatmentThe patient who benefited the longest from fostrox + Lenvima® remains on treatment after 12 months, with tumor